These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 3937664)
1. A clinical pharmacological study of a new type of vaginal delivery system for levonorgestrel. Landgren BM; Johannisson E; Xing S; Aedo AR; Diczfalusy E Contraception; 1985 Dec; 32(6):581-601. PubMed ID: 3937664 [TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic investigations with vaginal devices releasing levonorgestrel at a constant, near zero order rate. Landgren BM; Johannisson E; Masironi B; Diczfalusy E Contraception; 1982 Dec; 26(6):567-85. PubMed ID: 6820337 [TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic effects of ethinyl estradiol in women using vaginal devices releasing small doses of levonorgestrel at a constant rate. Toddyvalla V; Johannisson E; Landgren BM; Cekan SZ; Diczfalusy E Contraception; 1983 Jul; 28(1):21-39. PubMed ID: 6414759 [TBL] [Abstract][Full Text] [Related]
4. Morphometric study of the human endometrium following continuous exposure to levonorgestrel released from vaginal rings during 90 days. Johannisson E; Brosens I; Cornillie F; Elder M; White J; Sheppard B; Hourihan H; d'Arcangues C; Belsey EM Contraception; 1991 Apr; 43(4):361-74. PubMed ID: 1906792 [TBL] [Abstract][Full Text] [Related]
5. The interaction between sex hormone binding globulin and levonorgestrel released from vaginal rings in women. Cekan SZ; Jia M; Landgren BM; Diczfalusy E Contraception; 1985 Apr; 31(4):431-9. PubMed ID: 3924477 [TBL] [Abstract][Full Text] [Related]
6. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology. Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951 [TBL] [Abstract][Full Text] [Related]
7. Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and d-norgestrel. Mishell DR; Moore DE; Roy S; Brenner PF; Page MA Am J Obstet Gynecol; 1978 Jan; 130(1):55-62. PubMed ID: 619648 [TBL] [Abstract][Full Text] [Related]
8. Clinical and endocrinologic study of continuous levonorgestrel administration from subcutaneous solid polydimethylsiloxane rods. Roy S; Stanczyk F; Mishell DR; Lumkin M; Gentzschein E Contraception; 1980 Jun; 21(6):595-615. PubMed ID: 6775868 [TBL] [Abstract][Full Text] [Related]
9. The effect of deliberate omission of Trinordiol or Microgynon on the hypothalamo-pituitary-ovarian axis. Smith SK; Kirkman RJ; Arce BB; McNeilly AS; Loudon NB; Baird DT Contraception; 1986 Nov; 34(5):513-22. PubMed ID: 3102162 [TBL] [Abstract][Full Text] [Related]
10. Prostaglandin production in human endometrium following continuous exposure to low-dose levonorgestrel released from a vaginal ring. White JO; Sullivan MH; Patel L; Croxtall JD; d'Arcangues C; Belsey EM; Elder MG Contraception; 1991 Apr; 43(4):401-12. PubMed ID: 1649733 [TBL] [Abstract][Full Text] [Related]
11. Blood levels of levonorgestrel in women following vaginal placement of contraceptive pills. Alvarez F; Faundes A; Johansson E; Coutinho E Fertil Steril; 1983 Jul; 40(1):120-3. PubMed ID: 6407876 [TBL] [Abstract][Full Text] [Related]
12. Endometrial effects of levonorgestrel and estradiol: A Scanning electron microscopic study of the luminal epithelium. Nilsson O; Englund D; Weiner E; Victor A Contraception; 1980 Jul; 22(1):71-83. PubMed ID: 6774851 [TBL] [Abstract][Full Text] [Related]
13. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Landgren BM; Diczfalusy E Contraception; 1984 May; 29(5):437-46. PubMed ID: 6430642 [TBL] [Abstract][Full Text] [Related]
14. Serum levels of d-norgestrel, luteinizing hormone, follicle-stimulating hormone, estradiol, and progesterone in women during and following ingestion of combination oral contraceptives containing dl-norgestrel. Brenner PF; Mishell DR; Stanczyk FZ; Goebelsmann U Am J Obstet Gynecol; 1977 Sep; 129(2):133-40. PubMed ID: 900174 [TBL] [Abstract][Full Text] [Related]
15. Ovulatory dysfunction during continuous administration of low-dose levonorgestrel by subdermal implants. Faundes A; Brache V; Tejada AS; Cochon L; Alvarez-Sanchez F Fertil Steril; 1991 Jul; 56(1):27-31. PubMed ID: 1906017 [TBL] [Abstract][Full Text] [Related]
16. Intravaginal and intracervical devices for the delivery of fertility regulating agents. J Steroid Biochem; 1979 Jul; 11(1B):461-7. PubMed ID: 491617 [TBL] [Abstract][Full Text] [Related]
17. Plasma progesterone levels during long-term treatment with levonorgestrel silastic implants. Croxatto HB; Diaz S; Pavez M; Miranda P; Brandeis A Acta Endocrinol (Copenh); 1982 Oct; 101(2):307-11. PubMed ID: 6814139 [TBL] [Abstract][Full Text] [Related]
18. Endometrial vascular features prior to and following exposure to levonorgestrel. Hourihan HM; Sheppard BL; Belsey EM; Brosens IA Contraception; 1991 Apr; 43(4):375-85. PubMed ID: 1906793 [TBL] [Abstract][Full Text] [Related]
19. Serum concentrations of estradiol, progesterone, and levonorgestrel are not determinants of endometrial histology or abnormal bleeding in long-term Norplant implant users. Darney PD; Taylor RN; Klaisle C; Bottles K; Zaloudek C Contraception; 1996 Feb; 53(2):97-100. PubMed ID: 8838486 [TBL] [Abstract][Full Text] [Related]
20. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response. Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]